about
No xenotropic murine leukemia virus-related virus detected in fibromyalgia patientsTime dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approachEULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statementUse of Intra-Articular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.Clinical settings in knee osteoarthritis: Pathophysiology guides treatment.Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation.EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).PTH increases jaw mineral density in a rabbit model of osteoporosis.Selective IgA deficiency and spondyloarthropathy: a distinct disease?Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study.Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study.Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator.Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1beta-stimulated human osteoarthritic synoviocytes and chondrocytes.Physiological effects of oral glucosamine on joint health: current status and consensus on future research prioritiesGenetic variation in the nuclear factor kappaB pathway in relation to susceptibility to rheumatoid arthritis.EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.Targeting subchondral bone in osteoporotic osteoarthritis.Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis.A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA projectEULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)Prevalence of spondyloarthritis in Terceira, Azores: a population based studyA multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.A fibrin based model for rheumatoid synovitis.Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis.Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and FrailtyA sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitisTotal joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritisThe adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction.Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility.Lipid transport and metabolism in healthy and osteoarthritic cartilage.Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics.Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration.Improvement of experimental accelerated atherosclerosis by chondroitin sulphate.Subchondral bone as a key target for osteoarthritis treatment.Update on the use of abatacept for the treatment of rheumatoid arthritis.An OA phenotype may obtain major benefit from bone-acting agents.
P50
Q24633092-1689DE38-775B-4EC5-85CA-1B48BBFEC325Q24673561-59DE8BBB-ABB0-4C62-915C-461AA85383FCQ24674132-A392FD65-ED59-433E-A507-9D79123CA618Q26799421-1165AD69-7264-48C5-AD4F-02FDBA58F2A3Q30238805-CDE3600F-6029-49EC-8DC5-86364127E566Q30239888-08669209-A4B1-4A6E-AFA3-BA2BE012F862Q30750457-56E46A82-DC65-446A-A401-55E5EB81F43CQ31119321-B5E3AD92-0F2E-43D7-AA42-A534234D796DQ33260652-8DED1D9F-6D66-4CC9-A18C-8334754A2AD7Q33533559-A20798FA-3109-49E7-9CF6-181C1CDA6D04Q33562903-59032BA8-4AE3-45C0-8B59-8251979D1984Q34121289-F50469B9-7B42-432E-8074-3B9B59EDC0C4Q34393009-CA674326-495E-4097-889B-C52FC8CE2567Q34574562-774CBDFB-EB14-479E-B686-932EF1D8AEB2Q34611977-D83425E7-E22D-4F7A-9363-705AF6916D70Q34636799-60B3F819-3C2D-4DC0-808D-052D3D636C39Q34773968-53489F32-3026-41D4-A552-86A94DFA20F1Q35003750-438865A1-9857-42D1-8458-7B27BDA3C89CQ35109909-1E6DFC36-E5FE-494B-AC76-85149D404E2FQ35197151-0B619F8B-D5C9-416A-9CD7-1CFFAFF326E6Q35249579-A0A829B2-2D68-4C76-B1EF-66665DC3CBE2Q35549064-D0755D39-F8DD-4D86-AEAF-3446105537C6Q35551600-D38CC23B-2CCC-4066-88E2-45DFC3916620Q35554739-53E499D9-A2C4-4010-B638-906C53F1803DQ35596311-8A24059B-A92D-49D8-8447-1BC69EDA10E2Q35692131-290C111C-B25E-4B25-BCF2-2BF6751FB5DFQ35756739-395E039E-32CE-4EA3-8E29-C2CA7C56590CQ35894623-A3230B8A-9F00-432D-9BF4-80CAE371ECCCQ35953484-EEAB4C13-A90D-44D6-B4B4-9314154B1D19Q36003672-237A431E-456A-4FAE-B50D-223F3FA46C78Q36246148-49907BB1-8FF4-4354-9DC9-B29C0D0C32D2Q37072629-CEF9B333-DE7A-458B-8E5F-3B7EC545549CQ37206928-C80B51AB-2BE8-4F6F-BA6E-B2D220B0003EQ37291362-CC7B4A36-9DE8-43F5-AC33-2ABFAFAD141CQ37546387-2FCAFDDA-7090-4AAF-928D-032E80F47620Q37690217-071F7EB0-F9BE-410F-9823-8498310DEE15Q37732924-041DDDBB-943B-48D7-AFD4-6EBADDF0997AQ37941432-FE37F121-6997-45E2-8930-B4A6AC83E018Q38125240-F0EC98E4-0C13-4B84-90B5-C459831BBF8FQ38135574-E25C916C-3FF9-47D6-940B-A155AD398373
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gabriel Herrero-Beaumont
@en
Herrero-Beaumont G
@ast
Herrero-Beaumont G
@es
Herrero-Beaumont G
@nl
Herrero-Beaumont G
@sl
type
label
Gabriel Herrero-Beaumont
@en
Herrero-Beaumont G
@ast
Herrero-Beaumont G
@es
Herrero-Beaumont G
@nl
Herrero-Beaumont G
@sl
altLabel
Herrero-Beaumont G
@en
prefLabel
Gabriel Herrero-Beaumont
@en
Herrero-Beaumont G
@ast
Herrero-Beaumont G
@es
Herrero-Beaumont G
@nl
Herrero-Beaumont G
@sl
P106
P1153
56216985100
P21
P31
P3835
gabriel-herrero-beaumont2
P496
0000-0002-3241-991X